A little more confirmation of event timing:Page 9: Stated that...

A little more confirmation of event timing:

Page 9: Stated that key activities coming up 'in next quarter' were New Indications' and FDA progress

Page 10: Short Term Catalysts: (Second Quarter)
Type C FDA Minutes - late May
New Indications
EU Ph 2 design response

The "New Indications" was mentioned twice - seems that we'll get some comment, finally, in the next six weeks. Mark earlier in the presso said he was Very Excited about progress with NI and that they had consolidated their position with the granting of a new patent....

I watched a later presentation in which it was stated that 40% of all the world's deaths of 50 million people pa were made up of deaths from cancer (10 million) and an equal number from Septic Shock (10 mill) that was generally unrecognised as being such a major factor. 'Septic Shock' arose from the body's over-response from its immune system to combat infections....an auto immune disease - and that the company presenting was looking to develop a product to inhibit the cytokine storm that causes the over-response.....all very similar to what ANP may be targeting with CD 49 to reduce inflammation....confirmation of a huge unmet market need.